These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 34476803)

  • 1. Safety and antibody response after one and/or two doses of BNT162b2 Anti-SARS-CoV-2 mRNA vaccine in patients treated by CAR T cells therapy.
    Gastinne T; Le Bourgeois A; Coste-Burel M; Guillaume T; Peterlin P; Garnier A; Imbert BM; Drumel T; Mahe B; Dubruille V; Blin N; Lok A; Touzeau C; Tessoulin B; Jullien M; Vanthygem S; Béné MC; Moreau P; Le Gouill S; Chevallier P
    Br J Haematol; 2022 Jan; 196(2):360-362. PubMed ID: 34476803
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial.
    Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Chen P; Söderdahl G; Österborg A; Smith CIE; Wullimann D; Vesterbacka J; Lindgren G; Blixt L; Friman G; Wahren-Borgström E; Nordlander A; Gomez AC; Akber M; Valentini D; Norlin AC; Thalme A; Bogdanovic G; Muschiol S; Nilsson P; Hober S; Loré K; Chen MS; Buggert M; Ljunggren HG; Ljungman P; Aleman S;
    EBioMedicine; 2021 Dec; 74():103705. PubMed ID: 34861491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The 12-week kinetics of anti-SARS-CoV-2 antibodies in different haematological cancers after vaccination with BNT162b2.
    Marchesi F; Pimpinelli F; Sperandio E; Papa E; Falcucci P; Pontone M; di Martino S; de Latouliere L; Orlandi G; Morrone A; Ciliberto G; Mengarelli A;
    Br J Haematol; 2022 Jan; 196(2):362-367. PubMed ID: 34490627
    [No Abstract]   [Full Text] [Related]  

  • 4. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
    Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
    Front Immunol; 2022; 13():827306. PubMed ID: 35173736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Immunogenicity among Chimeric Antigen Receptor T Cell Therapy Recipients.
    Aleissa MM; Little JS; Davey S; Saucier A; Zhou G; Gonzalez-Bocco IH; Crombie JL; Looka A; Baden LR; Issa NC; Hammond SP; Jacobson CA; Sherman AC
    Transplant Cell Ther; 2023 Jun; 29(6):398.e1-398.e5. PubMed ID: 36906276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B Cell Response Induced by SARS-CoV-2 Infection Is Boosted by the BNT162b2 Vaccine in Primary Antibody Deficiencies.
    Pulvirenti F; Fernandez Salinas A; Milito C; Terreri S; Piano Mortari E; Quintarelli C; Di Cecca S; Lagnese G; Punziano A; Guercio M; Bonanni L; Auria S; Villani F; Albano C; Locatelli F; Spadaro G; Carsetti R; Quinti I
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients.
    Zitt E; Davidovic T; Schimpf J; Abbassi-Nik A; Mutschlechner B; Ulmer H; Benda MA; Sprenger-Mähr H; Winder T; Lhotta K
    Front Immunol; 2021; 12():704773. PubMed ID: 34220867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pronounced decline of anti-SARS-CoV-2 spike trimeric IgG and RBD IgG in baseline seronegative individuals six months after BNT162b2 vaccination is consistent with the need for vaccine boosters.
    Salvagno GL; Henry BM; Pighi L; De Nitto S; Gianfilippi G; Lippi G
    Clin Chem Lab Med; 2022 Jan; 60(2):e29-e31. PubMed ID: 34816677
    [No Abstract]   [Full Text] [Related]  

  • 9. T-cell and Antibody Response After 2 Doses of the BNT162b2 Vaccine in a Belgian Cohort of Kidney Transplant Recipients.
    Devresse A; Saad Albichr I; Georgery H; Yombi JC; De Greef J; Belkhir L; Mzougui S; Scohy A; Darius T; Buemi A; Goffin E; Kabamba B; Kanaan N
    Transplantation; 2021 Oct; 105(10):e142-e143. PubMed ID: 34310103
    [No Abstract]   [Full Text] [Related]  

  • 10. Myeloma patients with COVID-19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine.
    Gavriatopoulou M; Terpos E; Malandrakis P; Ntanasis-Stathopoulos I; Briasoulis A; Gumeni S; Fotiou D; Papanagnou ED; Migkou M; Theodorakakou F; Eleutherakis-Papaiakovou E; Kanellias N; Trougakos IP; Kastritis E; Dimopoulos MA
    Br J Haematol; 2022 Jan; 196(2):356-359. PubMed ID: 34528249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and Safety of COVID-19 Vaccine BNT162b2 for Patients with Solid Cancer: A Large Cohort Prospective Study from a Single Institution.
    Di Noia V; Pimpinelli F; Renna D; Barberi V; Maccallini MT; Gariazzo L; Pontone M; Monti A; Campo F; Taraborelli E; Di Santo M; Petrone F; Mandoj C; Ferraresi V; Ferretti G; Carlini P; Di Bella O; Conti L; La Malfa AM; Pellini R; Bracco D; Giannarelli D; Morrone A; Cognetti F
    Clin Cancer Res; 2021 Dec; 27(24):6815-6823. PubMed ID: 34583970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody response after 2 and 3 doses of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic cell transplant recipients.
    Maillard A; Redjoul R; Klemencie M; Labussière Wallet H; Le Bourgeois A; D'Aveni M; Huynh A; Berceanu A; Marchand T; Chantepie S; Botella Garcia C; Loschi M; Joris M; Castilla-Llorente C; Thiebaut-Bertrand A; François S; Leclerc M; Chevallier P; Nguyen S
    Blood; 2022 Jan; 139(1):134-137. PubMed ID: 34818411
    [No Abstract]   [Full Text] [Related]  

  • 13. Serological response following BNT162b2 anti-SARS-CoV-2 mRNA vaccination in haematopoietic stem cell transplantation patients.
    Attolico I; Tarantini F; Carluccio P; Schifone CP; Delia M; Gagliardi VP; Perrone T; Gaudio F; Longo C; Giordano A; Sgherza N; Curci P; Rizzi R; Ricco A; Russo Rossi A; Albano F; Larocca AMV; Vimercati L; Tafuri S; Musto P
    Br J Haematol; 2022 Feb; 196(4):928-931. PubMed ID: 34664267
    [No Abstract]   [Full Text] [Related]  

  • 14. Very Low Immunization Rate in Kidney Transplant Recipients After One Dose of the BNT162b2 Vaccine: Beware not to Lower the Guard!
    Georgery H; Devresse A; Yombi JC; Belkhir L; De Greef J; Darius T; Buemi A; Scohy A; Kabamba B; Goffin E; Kanaan N
    Transplantation; 2021 Oct; 105(10):e148-e149. PubMed ID: 33988543
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer.
    Shapiro LC; Thakkar A; Campbell ST; Forest SK; Pradhan K; Gonzalez-Lugo JD; Quinn R; Bhagat TD; Choudhary GS; McCort M; Sica RA; Goldfinger M; Goel S; Anampa JD; Levitz D; Fromowitz A; Shah AP; Sklow C; Alfieri G; Racine A; Wolgast L; Greenberger L; Verma A; Halmos B
    Cancer Cell; 2022 Jan; 40(1):3-5. PubMed ID: 34838186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2.
    Ebinger JE; Fert-Bober J; Printsev I; Wu M; Sun N; Prostko JC; Frias EC; Stewart JL; Van Eyk JE; Braun JG; Cheng S; Sobhani K
    Nat Med; 2021 Jun; 27(6):981-984. PubMed ID: 33795870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attenuated response to SARS-CoV-2 vaccine in patients with asymptomatic precursor stages of multiple myeloma and Waldenstrom macroglobulinemia.
    Konishi Y; Sklavenitis-Pistofidis R; Yue H; Ferrari F; Redd RA; Lightbody ED; Russo M; Perry J; Horowitz E; Justis AV; Shayegh NA; Savell A; Prescott J; Varmeh S; Nowak RP; Hamilton M; Auclair D; Marinac CR; Trippa L; Fischer ES; Ghobrial IM
    Cancer Cell; 2022 Jan; 40(1):6-8. PubMed ID: 34895486
    [No Abstract]   [Full Text] [Related]  

  • 18. Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2.
    Markewitz R; Juhl D; Pauli D; Görg S; Junker R; Rupp J; Engel S; Steinhagen K; Herbst V; Zapf D; Krüger C; Brockmann C; Leypoldt F; Dargvainiene J; Schomburg B; Sharifzadeh S; Nejad LS; Wandinger KP; Ziemann M
    Front Immunol; 2022; 13():811020. PubMed ID: 35126395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
    Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
    Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies.
    Ghione P; Gu JJ; Attwood K; Torka P; Goel S; Sundaram S; Mavis C; Johnson M; Thomas R; McWhite K; Darrall A; DeMarco J; Kostrewa J; Mohr A; Rivas L; Neiders M; Suresh L; Segal BH; Griffiths EA; Ramsperger V; Shen L; Hernandez-Ilizaliturri FJ
    Blood; 2021 Sep; 138(9):811-814. PubMed ID: 34189565
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.